

RESEARCH ACTIVITIES

(Q1) Research Projects: April 2013 - March 2014

No.	Name of PI	Project Title	Funded by
Anaesthesiology			
1	Dr. Jayshree Thakkar	Retrospective analysis of ventilator associated pneumonia	GCS/GCRI
2	Dr. Geeta Joshi Dr. Priti Sanghvi	Sphenopalatine block for head & neck cancer pain management	GCS/GCRI
Biochemistry Research			
3	Dr. Shilin Shukla Dr. Prabhudas Patel Dr. Hemangini Vora Dr. Manoj Shah	Immuno score as a new possible approach for the classification of colon cancer	GCS/GCRI-Multinational project
4	Dr. Prabhudas Patel	Contribution of vascular endothelial growth factor family in oral cancer progression	DMER
5	Dr. Prabhudas Patel	VEGF family expression in cancer cervix and its prognostic significance	GCS/GCRI
6	Dr. Prabhudas Patel	Prevalence of high risk HPV type 16 and 18 in cervical cancers in population from Gujarat, West India	GCS/GCRI
7	Dr. Jayendra Patel	Prevalence of HPV in carcinoma of buccal mucosa: a changing etiology and its' associated molecular targets	GCS/GCRI
8	Dr. Jayendra Patel	Analysis by 2D electrophoresis approach in oral cancer	DMER
9	Dr. Franky Shah	Study of diverse molecular markers in breast carcinoma with regard to p53 status	GCS/GCRI
10	Dr. Franky Shah	Role of vitamin D and vitamin D pathway genes in breast cancer	ICMR
Blood Bank			
11	Dr. Rima Kusumgar	Maximum surgical blood order schedule	GCS/GCRI
12	Dr. Rima Kusumgar	Seroprevalance of HIV, HbsAg and HCV among blood donors	GCS/GCRI
Cell Biology			
13	Dr. Prabhudas Patel	ALK rearrangements in NSCLC patients	Pfizer/GCRI
14	Dr. Manisha Brahmbhatt	Molecular cytogenetics as the laboratorial tool for diagnosis and management of patients with solid tumors	GCS/GCRI
15	Dr. Pina Trivedi	Clinical significance of cytogenetic and molecular cytogenetic studies in acute promyelocytic leukemia	GCS/GCRI

No.	Name of PI	Project Title	Funded by
Community Oncology			
16	Dr. Rakesh Vyas	Rural cancer registry Ahmedabad district	NCRP, ICMR, Bangalore
17	Dr. Rakesh Vyas	Population based cancer registry - Ahmedabad urban agglomeration area	NCRP, ICMR, Bangalore
18	Dr. Parimal Jivrajani	Effectiveness and safety of 2 vs 3 doses of HPV vaccine in preventing cervical cancer : an indian multicentric study	IARC, Lyon, France
19	Dr. Rakesh Vyas	Risk factors for breast cancer in india – an indox case control study and life-long vegetarianism and risk of colorectal cancer in india: an indox case control study	INDOX and the University of OXFORD,UK
Gynaecological Oncology			
20	Dr. Chetana Parekh	Prevalence of high risk human papilloma virus type 16 and type 18 in cervical cancers in population from gujarat, west india	GCS/GCRI
21	Dr. Archana Bharti Dr. Ava Desai	VEGF family expression in cancer cervix and its prognostic significance	GCS/GCRI
Immunohistochemistry & Flowcytometry			
22	Dr. Hemangini Vora	Detection of cancer stem cells in breast cancer patients by multiparameters	GCS/GCRI
23	Dr. Hemangini Vora	Detection of circulating tumor cells in breast cancer patients by multiparameter flowcytometry	GCS/GCRI
24	Dr. Hemangini Vora	Detection of minimal residual disease in acute lymphoblastic leukemia by multicolor flowcytometry	GCS/GCRI
25	Dr. Hemangini Vora	Detection of C-met receptor protein in never smoker lung cancer	DMER
26	Dr. Hemangini Vora	A study of EGFR downstream signaling pathway in never smoker lung cancer	DMER
27	Dr. Nilima Desai	Prognostic significance of MDM2 p53 protein expression, cyclinE and basal cytokeratin 5/6 in breast carcinoma	GCS/GCRI
28	Dr. Nilima Desai	Expression of FoxA1 and GATA-3 in breast cancer	DMER

No.	Name of PI	Project Title	Funded by
Medical Oncology			
29	Dr. Asha Anand	Basilea Pharmaceutica Ltd, /A phase III, double-blind, randomized study to evaluate the safety and efficacy of BAL8557 versus a Caspofungin followed by Voriconazole regimen in the treatment of [Isavuconazonium Sulphate (BAL8557), Isavuconazole (BAL4815)] WSA-CS-008	Quintiles Spectral Limited
30	Dr. Asha Anand	RLS/TP/2010/07–Prospective, multi-centric, open label, two arm, parallel group, active control, randomized, comparative clinical study to evaluate efficacy and safety of R-TPR-017 / MabThera® in patients with Non-Hodgkin's Lymphoma	Reliance Life Science
31	Dr. Sandip Shah	CAMN107A2404 a randomized phase III study of Imatinib dose optimization compared with Nilotinib in patients with Chronic Myelogenous Leukemia and suboptimal response to standard dose Imatinib	Novartis Healthcare
32	Dr. Sandip Shah	Study A8081014–entitled: Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of Crizotinib Versus Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in Previously Untreated Patients with Non-Squamous Carcinoma of the Lung Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus	Pfizer Ltd
33	Dr. Sandip Shah	GP13-301-A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 plus CVP vs. MabThera® plus CVP, Followed by GP2013 or MabThera® Maintenance Therapy in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma. Closed (International)	Sandoz-PPD
34	Dr. Harsha Pancal	B1931008 titled: An open-label, randomized, phase 3 study of Inotuzumab ozogamicin administered in combination with Rituximab compared to defined investigator's choice therapy in subjects with relapsed or refractory CD-22-positive aggressive non-hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy	Pfizer Ltd
35	Dr. Harsha Pancal	LUX BREAST-1, 1200.75: An open label, randomized phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment. Active(International)	Manipal
36	Dr. Harsha Pancal	A phase II/III Open label Multicentric Randomised trial to determine the safety and efficacy of Non-pegylated Liposomal Doxorubicin (Nudoxa) at two different dose levels as compared to doxorubicin in patients with metastatic breast cancer	Zydus Cadila
37	Dr. Sonia Parikh	A Phase II Clinical Study to evaluate the efficacy and safety of NRC-AN-019 in cancer patients failing prior standard therapies	Natco

No.	Name of PI	Project Title	Funded by
Medicinal Chemistry & Pharmacogenomic			
38	Dr. Rakesh Rawal	TGFBeta gene polymorphisms and breast cancer risk	DMER
39	Dr. Rakesh Rawal	Expression of transforming growth factor beta receptor II in breast carcinoma	DMER
40	Dr. Rakesh Rawal	Insulin like growth factor-1 gene expression in breast cancer	DMER
41	Dr. Rakesh Rawal	Isolation and characterization of leukemic stem cells to predict drug response and resistance	GSBTM
42	Dr. Rakesh Rawal	Developing an in-vitro model to stimulate Imatinib resistance in Ph+ Myeloid Progenitor Cells	DMER
43	Dr. Rakesh Rawal	Deciphering microRNA dynamics in Imatinib resistance Ph+ CML: in-vitro approach	GSBTM
44	Dr. Rakesh Rawal	To assess the role of micro RNA and epigenetic regulation of imatinib resistance in chronic myeloid leukemia	ICMR
Microbiology			
45	Dr. Parijath Goswami	Detection of etiological agents in acute respiratory tract infection by immunofluorescence technique in cancer patients	GCS/GCRI
46	Dr. Parijath Goswami	Detection of Clostridium difficile infection from patients suffering with diarrhoea in particular reference to Antibiotic Associated Diarrhoea (AAD) in cancer hospital	GCS/GCRI
47	Dr. Parijath Goswami	Prevalence of systemic fungal infections in oncology patients by Serodiagnosis	GCS/GCRI
48	Dr. Parijath Goswami	Role of sepsis screen and blood cultures in the early diagnosis of Septicemia in febrile neutropenia patients	GCS/GCRI
49	Dr. Parijath Goswami	Antimicrobial profile of hospital acquired Methicillin resistant staphylococcus aureus (HA-MRSA) and phenotypic and genotypic detection of antimicrobial resistance	GCS/GCRI
50	Dr. Foram Patel	Epidemiology of healthcare associated infection and molecular diagnosis of antibiotic resistance in an intensive care unit	GCS/GCRI
Molecular Endocrinology			
51	Dr. Nandita Ghosh	Role of inflammatory mediators in thyroid tumorigenesis	GCS/GCRI
52	Dr. Nandita Ghosh	Role of thymidylate synthase (TS) and excision repair cross complementation group i (ERCC-I) gene in patients with colorectal carcinoma	GCS/GCRI

No.	Name of PI	Project Title	Funded by
53	Dr. Nandita Ghosh	Mutation in exon 14 of Dihydropyrimidine (DPYD) gene and its association with 5-Flourouracil chemotherapy in colorectal cancer	GCS/GCRI
54	Dr. Nandita Ghosh	Clinical utility of circulating soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with locally advanced colorectal cancer	DMER
55	Dr. Trupti Trivedi	Clinical significance of ABCG2, Oct-4 and Nanog in oral squamous cell carcinoma	DMER
56	Dr. Trupti Trivedi	Clinical relevance of stem cell markers in patients with locally advanced OSCC	GCS/GCRI
57	Dr. Trupti Trivedi	MRN complex (Mre11/Rad50/Nsb1) proteins in oral cancer	DMER
58	Dr. Trupti Trivedi	Micro RNA-24 Expression in oral cancer	DMER
59	Dr. Trupti Trivedi	Clinical Relevance of stem cell markers in patients with locally advanced oral squamous cell carcinoma	GCS/GCRI
60	Dr. Trupti Trivedi	Role of DNA damage repair pathway in oral cancer: As predictive markers for therapy response	GCS/GCRI
Surgical Oncology			
61	Dr. Anoop Puri	Impact of esophagectomy on health related quality of life in patients with esophageal cancer	GCS/GCRI
62	Dr. Anoop Puri	Breast cancer awareness among female attendants of the patients visiting GCRI	GCS/GCRI
63	Dr. Anoop Puri	Breast cancer awareness among nurses at GCRI	GCS/GCRI